FEATURES OF DISORDERS OF HYDROCARBON AND LIPID METABOLISM IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH NORMAL AND OVERWEIGHT
DOI:
https://doi.org/10.11603/mcch.2410-681X.2021.i3.12582Keywords:
myocardial infarction, overweight, obesity, insulin resistance, visceral fat, carbohydrate metabolism, fat metabolismAbstract
Introduction. In terms of prevalence and adverse effects, acute myocardial infarction (MI) remains one of the most pressing problems in cardiology for many years.
The aim of the study – comparative analysis of indicators of metabolism of hydrocarbon and lipid metabolism in patients with MI with normal and elevated body mass index and persons with metabolic syndrome.
Research Methods. The study included 77 men with acute ST-segment elevation myocardial infarction. All patients had body weight (kg), height (m), body mass index – BMI (kg/m2), waist circumference (WC) and hip circumference (HC), WC/HC ratio. By BMI, patients were divided into three groups: normal body weight (18.5<BMI<24.9 kg/m2) – group 1 (n=23); overweight (25<BMI<29.9 kg/m2) – group 2 (n=33), obesity (BMI>30 kg/m2) – group 3 (n=21). The biochemical study determined the levels of cardiac troponins I and T, CF fraction of creatine phosphokinase (CPK-MB), blood lipid spectrum, glycemia and insulin concentration at baseline, on an empty stomach after 8 hours of fasting and for 12 days. At the same time, patients were also determined postprandial blood glucose levels, and if necessary, performed a test for tolerance to carbohydrates according to conventional methods. Statistical processing of the obtained results was performed using the statistical software package "Statistica 10.0" and the program "Microsoft Exel-2013".
Results and Discussion. At baseline, in most patients of all study groups, the indicators of WC and WC/HC exceeded the upper limit of the gender norm: in group 1 – in 69.5 % (n=16), in group 2 – in 81.8 % (n=27), in group 3 – in 85.7 % (n=18) patients (p<0.05), which indicates dysmetabolic disorders in the body not only in patients with overweight and obesity, but also in patients with normal body weight. At the same time, these patients were diagnosed with hyperglycemia, hyperinsulinemia and atherogenic dyslipoproteinemia.
Conclusion. The development of insulin resistance and metabolic syndrome in patients with MI is accompanied by significant disorders of carbohydrate and lipid metabolism, manifested by hyperglycemia, hyperinsulinemia and atherogenic dyslipidemia in acute and subacute periods of the disease in patients with visceral obesity.
References
Gach O. Acute coronary syndrome / O. Gach, Z. Husseini, P. Lancellotti // Rev. Med. Liege. – 2018. – 73 (5–6). – P. 243–250.
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal. – 2012. – 33 (20). – P. 2569–2619.
Impact of metabolic syndrome on clinical severity and long-term prognosis in patients with myocardial infarction with ST-segment elevation / M. Lovic, D. Djordjevic, I. Tasic [et al.] // Hellenic Journal of Cardiology. – 2018. – 59 (4). – P. 226–231.
Kelli H. Cardio metabolic syndrome: A global epidemic / H. Kelli, I. Kassas, O. Lattouf // J Diabetes Metab. – 2015. – 6 (3). – P. 263–275.
IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040 / K. Ogurtsova, J. Fernandes, Y. Huang [et al.] // Diabetes Research and Clinical Practice. – 2017. – 128. – P. 40–50. DOI: 10.1016/j.diabres.2017.03.024.
Christopher Nolan J. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift / J. Christopher Nolan, M. Prentki // SAGE Jorna. – 2019. – 16 (2). – P. 118–127. – Access mode : https://doi.org/10.1177/1479164119827611
Sperling L. The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome / L. Sperling, J. Mechanick, I. Neeland // J. Am. Coll. Cardiol. – 2015. – 66 – P. 1050–1067.
Уніфікований клінічний протокол екстреної, первинної, вторинної (спеціалізованої) та третинної (високоспеціалізованої) медичної допомоги та медичної реабілітації хворих на гострий коронарний синдром з елевацією сегмента ST / М. К. Хобзей, Ю. М. Сіренко, А. В. Степаненко [та ін.] // Наказ МОЗ України від 02.07.2014 р. № 455.
Камінський О. В. Офіційні критерії діагностики цукрового діабету, нормоглікемія і самоконтроль глікемії // Міжнар. ендокрин. журн. – 2017. – 13, № 3. – C. 184–190.
Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression / S. Lim, N. Kakoly, J. Tan // Obes. Rev. – 2018. – 20. – P. 339–352.
Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors / D.Blake, J. Meigs, D. Muller [et al.] // Diabetes. – 2004. – 53 (8). – P. 2095–2100.
β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis / E. Ferrannini, A. Gastaldelli, Y. Miyazaki [et al.] // J. Clin. Endocrinol. Metab. – 2005. – 90. – P. 493–500.
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus / H. Ginsberg, P. MacCallum // J. Cardiometab. Syndr. – 2009. – 4 (2). – P. 113–119.
REFERENCES
Gach, O., Husseini, Z., & Lancellotti, P. (2018). Acute coronary syndrome. Rev. Med. Liege, 73 (5-6), 243-250.
(2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal, 33 (20), 2569-2619.
Lovic, M., & Djordjevic, D. (2018). Tasic impact of metabolic syndrome on clinical severity and long-term prognosis in patients with myocardial infarction with ST-segment elevation. Hellenic Journal of Cardiology, 59 (4), 226-231
Kelli, H., Kassas, I., Lattouf, O.(2015) Cardio metabolic syndrome: A global epidemic. J. Diabetes Metab., 6, 263-275.
Ogurtsova, K., Fernandes, J., & Huang, Y. (2017). IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50. DOI: 10.1016/j.diabres.2017.03.024.
Christopher, J., & Prentki, M. (2019). Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. SAGE Jornal, 16 (2), 118-127. Retrieved from: https://doi.org/10.1177/1479164119827611
Sperling, L., Mechanick, J., & Neeland, I. (2015). The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J. Am. Coll. Cardiol., 66, 1050-1067.
Khobzey, M.K., Sirenko, Yu.M., & Stepanenko, A.V. (2014). Nakaz MOZ Ukrainy № 455 vid 02.07.2014. Unifikovanyi klinichnyi protokol ekstrenoi, pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy ta medychnoi reabilitatsii khvorykh na hostryi koronarnyi syndrom z elevatsiieiu sehmenta ST [Ministry of Health of Ukraine Order No. 455 dated 2 July 2014. Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (highly specialized) medical care and medical rehabilitation of patients with acute coronary syndrome with ST segment elevation]. [in Ukrainian].
Kaminskyi, O.V. (2017). Ofitsiini kryterii diahnostyky tsukrovoho diabetu, normohlikemiia i samokontrol hlikemii [Official criteria for the diagnosis of diabetes, normoglycemia and glycemic self-control]. Mizhnarodnyi endokrynolohichnyi zhurnal – International Journal of Endocrinology, 13 (3), 184-190 [in Ukrainian].
Lim, S., Kakoly, N., & Tan, J. (2018). Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes. Rev., 20, 339-352.
Blake, D., Meigs, J., & Muller, D. (2004). Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors. Diabetes, 53 (8), 2095-2100.
Ferrannini, E., Gastaldelli, A., & Miyazaki, Y. (2005). β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab., 90, 493-500.
Ginsberg, H., & MacCallum, P. (2009). The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr., 4 (2), 113-119.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
